Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV

Inclusion criteria

(Patients are eligible to be included in the study only if they meet all of the following criteria):

• Cancer patients, age ≥ 18 years and ≤75 years, ECOG score 0-2 points, receiving cisplatin-containing doublet chemotherapy such as cisplatin + gemcitabine / albumin paclitaxel / etoposide /fluorouracil / irinotecan / temozolomide as first line treatment;
• Life expectancy ≥ 3 months;
• Leucocytes≥3,000/uL;
• AST≤2.5 × upper limit of normal;
• Bilirubin ≤1.5 × upper limit of normal;
• Serum creatinine ≤ 1.5 × upper limit of normal.

Exclusion criteria

(Patients will be excluded if any of the following criteria is met):

• History of CNS disease, such as brain metastases or epilepsy;
• Use of other antipsychotic drugs (such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone, or such treatment is under scheduling during the study) within 30 days before enrollment; long-term use of phenothiazine as an antipsychotic agent;
• Concurrent use of pharyngeal or abdominal radiotherapy;
• Concurrent use of quinolone antibiotics;
• Chronic alcoholism;
• Known hypersensitivity to olanzapine;
• Know arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within 6 months;
• Known uncontrolled diabetes mellitus;
• Vomiting or retching 24 hours before chemotherapy;
• Use of anti-emesis drugs 48 hours before chemotherapy;
• Concurrent use of amifostine;
• Concurrent use of corticosteroids and the only anti-allergic choice is corticosteroids